These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 21145912

  • 1. A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice.
    Granadillo M, Vallespi MG, Batte A, Mendoza O, Soria Y, Lugo VM, Torrens I.
    Vaccine; 2011 Jan 29; 29(5):920-30. PubMed ID: 21145912
    [Abstract] [Full Text] [Related]

  • 2. A novel self-assembled nanoparticle vaccine with HIV-1 Tat₄₉₋₅₇/HPV16 E7₄₉₋₅₇ fusion peptide and GM-CSF DNA elicits potent and prolonged CD8⁺ T cell-dependent anti-tumor immunity in mice.
    Tang J, Yin R, Tian Y, Huang Z, Shi J, Fu X, Wang L, Wu Y, Hao F, Ni B.
    Vaccine; 2012 Feb 01; 30(6):1071-82. PubMed ID: 22178528
    [Abstract] [Full Text] [Related]

  • 3. The contribution of NT-gp96 as an adjuvant for increasing HPV16 E7-specific immunity in C57BL /6 mouse model.
    Mohit E, Bolhassani A, Zahedifard F, Taslimi Y, Rafati S.
    Scand J Immunol; 2012 Jan 01; 75(1):27-37. PubMed ID: 21916914
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
    Peng S, Ferrall L, Gaillard S, Wang C, Chi WY, Huang CH, Roden RBS, Wu TC, Chang YN, Hung CF.
    mBio; 2021 Jan 19; 12(1):. PubMed ID: 33468698
    [Abstract] [Full Text] [Related]

  • 6. Recombinant Leishmania tarentolae encoding the HPV type 16 E7 gene in tumor mice model.
    Salehi M, Taheri T, Mohit E, Zahedifard F, Seyed N, Taslimi Y, Sattari M, Bolhassani A, Rafati S.
    Immunotherapy; 2012 Nov 19; 4(11):1107-20. PubMed ID: 23194361
    [Abstract] [Full Text] [Related]

  • 7. Immuno-Stimulating Peptide Derived from HMGB1 is More Effective Than the N-Terminal Domain of Gp96 as an Endogenous Adjuvant for Improvement of Protein Vaccines.
    Talebi S, Bolhassani A, Azad TM, Arashkia A, Modaresi MH.
    Protein Pept Lett; 2017 Nov 19; 24(3):190-196. PubMed ID: 28000571
    [Abstract] [Full Text] [Related]

  • 8. A Genetically Modified attenuated Listeria Vaccine Expressing HPV16 E7 Kill Tumor Cells in Direct and Antigen-Specific Manner.
    Jia YY, Tan WJ, Duan FF, Pan ZM, Chen X, Yin YL, Jiao XA.
    Front Cell Infect Microbiol; 2017 Nov 19; 7():279. PubMed ID: 28706878
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. DNA vaccine encoding HPV-16 E7 with mutation in L-Y-C-Y-E pRb-binding motif induces potent anti-tumor responses in mice.
    Bahrami AA, Ghaemi A, Tabarraei A, Sajadian A, Gorji A, Soleimanjahi H.
    J Virol Methods; 2014 Sep 19; 206():12-8. PubMed ID: 24880067
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. DNA vaccine encoding endosome-targeted human papillomavirus type 16 E7 protein generates CD4+ T cell-dependent protection.
    Brulet JM, Maudoux F, Thomas S, Thielemans K, Burny A, Leo O, Bex F, Hallez S.
    Eur J Immunol; 2007 Feb 19; 37(2):376-84. PubMed ID: 17274002
    [Abstract] [Full Text] [Related]

  • 13. Different domains of glycoprotein 96 influence HPV16 E7 DNA vaccine potency via electroporation mediated delivery in tumor mice model.
    Daemi A, Bolhassani A, Rafati S, Zahedifard F, Hosseinzadeh S, Doustdari F.
    Immunol Lett; 2012 Dec 17; 148(2):117-25. PubMed ID: 23085605
    [Abstract] [Full Text] [Related]

  • 14. Enhanced anti-tumor effects of HPV16E7(49-57)-based vaccine by combined immunization with poly(I:C) and oxygen-regulated protein 150.
    Chen S, Ou R, Tang J, Deng X, Wu Y, van Velkinburgh JC, Ni B, Xu Y.
    Cancer Epidemiol; 2013 Apr 17; 37(2):172-8. PubMed ID: 23127963
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A novel "priming-boosting" strategy for immune interventions in cervical cancer.
    Liao S, Zhang W, Hu X, Wang W, Deng D, Wang H, Wang C, Zhou J, Wang S, Zhang H, Ma D.
    Mol Immunol; 2015 Apr 17; 64(2):295-305. PubMed ID: 25575128
    [Abstract] [Full Text] [Related]

  • 17. Comparison of six cell penetrating peptides with different properties for in vitro and in vivo delivery of HPV16 E7 antigen in therapeutic vaccines.
    Shahbazi S, Bolhassani A.
    Int Immunopharmacol; 2018 Sep 17; 62():170-180. PubMed ID: 30015237
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cell-mediated immune response to human papillomavirus 16 E7 peptide pools in patients with cervical neoplasia.
    Lee YS, Lee CW, Song MJ, Ho EM, Kim CJ, Park TC, Kim TG, Park JS.
    Acta Obstet Gynecol Scand; 2011 Dec 17; 90(12):1350-6. PubMed ID: 21916856
    [Abstract] [Full Text] [Related]

  • 20. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
    Esquerré M, Momot M, Goubier A, Gonindard C, Leung-Theung-Long S, Misseri Y, Bissery MC.
    Vaccine; 2017 Mar 13; 35(11):1509-1516. PubMed ID: 28196735
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.